Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silic… Read more
Market Cap & Net Worth: Qiagen NV (QGEN)
Qiagen NV (NYSE:QGEN) has a market capitalization of $8.56 Billion ($8.56 Billion) as of March 18, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #1894 globally and #1372 in its home market, demonstrating a -4.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qiagen NV's stock price $41.54 by its total outstanding shares 205998950 (206.00 Million).
Qiagen NV Market Cap History: 2015 to 2026
Qiagen NV's market capitalization history from 2015 to 2026. Data shows growth from $5.70 Billion to $8.56 Billion (4.73% CAGR).
Qiagen NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qiagen NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.43x
Qiagen NV's market cap is 4.43 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
21.80x
Qiagen NV's market cap is 21.80 times its annual earnings
363.13x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.78 Billion | $1.34 Billion | $80.40 Million | 4.32x | 71.85x |
| 2017 | $6.38 Billion | $1.42 Billion | $40.39 Million | 4.50x | 157.86x |
| 2018 | $7.10 Billion | $1.50 Billion | $190.38 Million | 4.73x | 37.31x |
| 2019 | $6.97 Billion | $1.53 Billion | -$41.45 Million | 4.57x | N/A |
| 2020 | $10.90 Billion | $1.87 Billion | $359.19 Million | 5.83x | 30.33x |
| 2021 | $11.46 Billion | $2.25 Billion | $512.60 Million | 5.09x | 22.35x |
| 2022 | $10.28 Billion | $2.14 Billion | $423.21 Million | 4.80x | 24.29x |
| 2023 | $8.95 Billion | $1.97 Billion | $341.30 Million | 4.56x | 26.23x |
| 2024 | $9.17 Billion | $1.98 Billion | $83.59 Million | 4.64x | 109.74x |
| 2025 | $9.26 Billion | $2.09 Billion | $424.88 Million | 4.43x | 21.80x |
Competitor Companies of QGEN by Market Capitalization
Companies near Qiagen NV in the global market cap rankings as of March 18, 2026.
Key companies related to Qiagen NV by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Qiagen NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Qiagen NV's market cap moved from $5.70 Billion to $ 8.56 Billion, with a yearly change of 4.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.56 Billion | -7.63% |
| 2025 | $9.26 Billion | +0.99% |
| 2024 | $9.17 Billion | +2.45% |
| 2023 | $8.95 Billion | -12.91% |
| 2022 | $10.28 Billion | -10.27% |
| 2021 | $11.46 Billion | +5.17% |
| 2020 | $10.90 Billion | +56.36% |
| 2019 | $6.97 Billion | -1.89% |
| 2018 | $7.10 Billion | +11.38% |
| 2017 | $6.38 Billion | +10.38% |
| 2016 | $5.78 Billion | +1.34% |
| 2015 | $5.70 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Qiagen NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.56 Billion USD |
| MoneyControl | $8.56 Billion USD |
| MarketWatch | $8.56 Billion USD |
| marketcap.company | $8.56 Billion USD |
| Reuters | $8.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.